Specialty Pharmacy

Rucaparib is the only PARP inhibitor demonstrated to have better outcomes than a docetaxel-containing control arm, according to researchers.

QR codes are currently used in various health care settings, such as in hospitals for patient verification, but more recently for health care-related education.

Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.

Higher C-reactive protein levels have been linked to cognition problems among older breast cancer survivors.

Two Houston Methodist cancer researchers were granted a quarter-million dollars each to study some of the most lethal forms cancer, including triple-negative breast cancer and multiple myeloma.

Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.

Relapses remain a challenge in treating patients with leukemia.

The FDA approved the only companion diagnostic that is indicated to assess low levels of HER2 proteins in patients with metastatic breast cancer.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

Phoenix-area Walgreens pharmacist Matthew Pruitt earns top honor as 2022 Pharmacist of the Year.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.

Despite significant advances in cancer treatment, molecular sequencing and enrollment of Black patients in clinical trials are still less than that of White and Asian patients.

Yvonne Chen, PhD, discusses her research to engineer more safe and effective next-generation CAR-T therapy for cancer immunotherapy.

IDH inhibitors show encouraging results in patients with myelodysplastic syndrome, but longer follow ups are needed in a larger patient population to confirm the results.

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Two Houston Methodist cancer researchers were granted a quarter of a million dollars each to study some of the most lethal cancers.

New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.

KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.

Combination treatment with ibrutinib found to increase median progression-free survival by 2.3 years compared to the placebo.

There were approximately 250,000 new cases of prostate cancer identified in the United States in 2021, which is considered approximately 13% of all cancer cases.

The value of a patient-first approach and telehealth for addressing the complex health coordination needs of those with these pulmonary conditions has never been more critical.